Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-1769 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| mRNA-1769 Dose A | EXPERIMENTAL | Participants will receive intramuscular (IM) injection of mRNA-1769 at Dose A on Day 1 and Day 29. |
| mRNA-1769 Dose B | EXPERIMENTAL | Participants will receive IM injection of mRNA-1769 at Dose B on Day 1 and Day 29. |
| mRNA-1769 Dose C | EXPERIMENTAL | Participants will receive IM injection of mRNA-1769 at Dose C on Day 1 and Day 29. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive IM injection of placebo matched to mRNA-1769 on Day 1 and Day 29. |
| Name | Type | Description |
|---|---|---|
| mRNA-1769 | BIOLOGICAL | Sterile liquid for injection |
| Placebo | OTHER | 0.9% sodium chloride injection (normal saline) |
Inclusion Criteria: * Has a body mass index (BMI) between ≥18 kilogram per square meter (kg/m\^2) to ≤39 kg/m\^2. * For female participants of childbearing potential: must have a negative highly sensitive pregnancy test with 28 days before the first dose of study drug, uses approved contraception d...
mRNA-1769 is an investigational mRNA vaccine developed by Moderna, Inc. for the prevention of smallpox. It is in Phase 1 clinical development and has been studied in healthy adult participants. It is a vaccine candidate and is not approved for use.
mRNA-1769 is being developed for smallpox, with the related condition mpox also listed among the conditions studied in its clinical trial. It is an investigational vaccine candidate and has not been approved for any indication.
mRNA-1769 is developed by Moderna, Inc., which trades on the Nasdaq under the ticker MRNA. Moderna is the sponsor of the clinical program evaluating the vaccine candidate.
mRNA-1769 is in Phase 1 clinical development. Its single Phase 1 trial has been completed. The vaccine candidate is investigational and has not been approved by the FDA or any other regulatory agency.
mRNA-1769 has been evaluated in one Phase 1 trial, NCT05995275, titled a study of the safety, tolerability, and immune response of a range of doses of mRNA-1769 compared with placebo in healthy participants. The trial enrolled 351 participants in the United Kingdom and is completed.
The Phase 1 trial NCT05995275 was a randomized, double-blind, placebo-controlled study of a range of doses of mRNA-1769 in healthy participants aged 18 to under 50 years. It enrolled 351 participants in the United Kingdom and has been completed.